Oxford Immunotec to receive $28M patent payout

BY Zachary Comeau

Oxford Immunotec's Marlborough offices.

U.K.-based Oxford Immunotec, with U.S. headquarters in Marlborough, has announced a $27.5 million settlement with a Germany-based company after a lengthy patent infringement suit.
Diagnostics firm Qiagen N.V., based in Hilden, Germany, will pay Oxford Immunotec the settlement for the right for a royalty-free, non-exclusive license to sell tuberculosis tests to current and future customers.
The settlement includes general releases of all parties with no admissions of wrongdoing, Oxford Immunotec said in a press release Friday.
Oxford Immunotec in a 2015 suit claimed patent infringement of tests it developed to diagnose tuberculosis in vitro.
A federal judge in September denied Oxford Immunotec a preliminary injunction and allowed Qiagen and two other companies to sell its tuberculosis tests before a scheduled trial in January, but the judge noted Oxford Immunotec was likely to win at trial.